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Abstract
Background: The numbers of oncogenic mutations required for transformation are uncertain but
may be inferred from how cancer frequencies increase with aging. Cancers requiring more
mutations will tend to appear later in life. This type of approach may be confounded by biologic
heterogeneity because different cancer subtypes may require different numbers of mutations. For
example, a sporadic cancer should require at least one more somatic mutation relative to its
hereditary counterpart.
Methods: To better estimate numbers of mutations before transformation, 1,022 colorectal
cancers were classified with respect to microsatellite instability (MSI) and germline DNA mismatch
repair mutations characteristic of hereditary nonpolyposis colorectal cancer (HNPCC). MSI-
cancers were also classified with respect to clinical stage. Ages at cancer and a Bayesian algorithm
were used to estimate the numbers of oncogenic mutations required for transformation for each
cancer subtype.
Results: Ages at MSI+ cancers were consistent with five or six oncogenic mutations for hereditary
(HNPCC) cancers, and seven or eight mutations for its sporadic counterpart. Ages at cancer were
consistent with seven mutations for sporadic MSI- cancers, and were similar (six to eight mutations)
regardless of clinical cancer stage.
Conclusion: Different biologic subtypes of colorectal cancer appear to require different numbers
of oncogenic mutations before transformation. Sporadic MSI+ cancers may require more than a
single additional somatic alteration compared to hereditary MSI+ cancers because the epigenetic
inactivation of MLH1 commonly observed in sporadic MSI+ cancers may be a multistep process.
Interestingly, estimated numbers of MSI- cancer mutations were similar (six to eight mutations)
regardless of clinical cancer stage, suggesting a propensity to spread or metastasize does not
require additional mutations after transformation. Estimates of oncogenic mutation numbers may
help explain some of the biology underlying different cancer subtypes.
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Background
Cancer is thought to arise through a multistep process
involving sequential cycles of mutation and selection [1].
The identities and numbers of mutations required for
transformation are uncertain, but perhaps six general cel-
lular functions are typically altered [2]. Numbers of onco-
genic mutations may also be inferred from the age-related
increases in frequencies observed with many cancer types.
For example, logarithms of cancer frequencies versus age
typically yield straight lines, with slopes proportional to
numbers of cancer mutations [3].
Colorectal cancer epidemiology is consistent with approx-
imately five to seven oncogenic mutations before transfor-
mation [3-6]. The variability in estimated numbers of
mutations may reflect a number of differences. For exam-
ple, estimates vary between populations, with five to six
mutations in England and six to seven mutations in Fin-
land [4]. Recent advances in cancer genetics also reveal
biologic colorectal cancer heterogeneity. Approximately
5% of all colorectal cancers have strong familial predispo-
sitions and arise in individuals with germline mutations
in critical susceptibility loci [7]. Such hereditary cancers
(familial adenomatous polyposis (FAP) and hereditary
nonpolyposis colorectal cancer (HNPCC)) typically
present at younger ages and should require fewer somatic
mutations than their sporadic counterparts because one
mutation is inherited.
Genetic instability also divides colorectal cancers into two
groups [8]. Approximately 10 to 15% of sporadic cancers
exhibit microsatellite instability (MSI) secondary to
somatic loss of DNA mismatch repair (MMR). Most other
cancers exhibit chromosomal instability (CIN) character-
ized by aneuploidy and loss of heterozygosity (LOH)
[7,8]. CIN and MSI+ colorectal cancers have different
characteristics with respect to mutated loci, tumor loca-
tion, morphology, and clinical outcomes [7,8].
Numbers of oncogenic mutations may differ between can-
cer subtypes. Therefore, colorectal cancers arising in a
population-based setting were molecularly classified as
either sporadic or hereditary, and MSI+ or MSI-. Cancers
were also classified with respect to clinical stage because
additional mutations may be required for invasion or
metastasis. Ages at cancer for each subgroup were used to
infer numbers of mutations required for each type of
colorectal cancer.
Methods
Specimens
MSI status was determined for 1,022 colorectal cancers
sampled from nine large regional hospitals in southeast-
ern Finland as part of a study to characterize genetic alter-
ations in a well-defined population [9]. The cancers
represent approximately 60% of all colorectal cancers
removed from this population in 1994 to 1998 [9]. Germ-
line mutations in MLH1 or MSH2 were detected by allelic
specific PCR assays (for the two common Finnish MLH1
germline mutations) or by direct genomic sequencing of
coding exons [9]. The data can be downloaded from the
following website: http://www.cmb.usc.edu/people/
petercal/. Approval for this research was obtained from
the appropriate ethics committees, which are in compli-
ance with the Helsinki Declaration.
A second data set (SEER 11 Regs Public-Use, Nov 2001
Sub (1992–1999)) was obtained from the Surveillance,
Epidemiology, and End Results (SEER) Program, a popu-
lation-based registry in the United States of America that
records all cancers regardless of clinical treatment [10]. A
total of 108,275 records were analyzed for ages at cancer
selected by site (colon and rectum), race (white), histol-
ogy (adenocarcinoma, ICD-0-2 codes 8000–8500), and
stage (localized, regional, or distant). These cancers were
not characterized with respect to HNPCC or MSI.
Quantitative analysis
Numbers of oncogenic alterations (genetic mutations or
epigenetic alterations) required for transformation were
estimated from ages at cancer using a Bayesian approach
as previously described [11]. This method requires the use
of a life table from census data: for the Finnish data set we
used a Finnish life table from the World Health Organiza-
tion website http://www.who.int/countries/fin/en, for the
SEER dataset we used a United States life table as
described previously [11]. The model assumes the first vis-
ible clonal expansion occurs at the time of transformation
and ignores the interval after transformation. The analysis
ignores temporal trends, which may influence our muta-
tion estimates.
For the SEER dataset, we also fit our model for cancer pro-
gression [11] with the inferential method described in ref-
erence 12. This method does not require a life table, but
unlike our method it does require information on all the
cancer cases for the population at risk. Therefore this
method is appropriate for analysing the SEER dataset but
not the Finnish dataset. Our method [11] is appropriate
for analysing both datasets. For the SEER dataset, the two
methods inferred the same number of mutations required
for cancer.
Results
The presence or absence of MSI was determined for 1,022
colorectal cancers obtained from nine large regional hos-
pitals in southeastern Finland [9]. There were 895
(87.6%) MSI- cancers and 127 (12.4%) MSI+ cancers. The
MSI+ cancers were further classified as sporadic (N = 98 or
9.6% of all cancers) or HNPCC (N = 29 or 2.9% of allBMC Cancer 2005, 5:126 http://www.biomedcentral.com/1471-2407/5/126
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cancers) based on germline MLH1 or MSH2 mutations
(Table 1).
Ages at cancer can be used to estimate likely numbers of
oncogenic mutations required before transformation [3-
6,11]. Average ages for sporadic MSI+, MSI-, and HNPCC
cancers were respectively 71.5, 67.5, and 50.3 years (Fig-
ure 1A). For HNPCC cancers, estimated numbers of onco-
genic mutations were between four and seven (95%
credibility interval), with the most likely value of five
mutations (Table 1). For MSI+ sporadic cancers, estimated
numbers of mutations were between six and nine (95%
credibility interval) with more likely values of seven or
eight mutations. The most likely number of mutations
was seven for sporadic MSI- cancers.
Duke's stage and age at clinical presentation (Figure 1B)
were documented for 884 of the 895 MSI- sporadic can-
cers (Table 1). Average ages were 68.6 years for stage A,
69.0 years for stage B, 65.2 years for stage C, and 65.4
years for stage D. The most likely numbers of oncogenic
mutations were seven for stage A cancers, eight for stage B
cancers, and six for stage C or D cancers (Table 1).
Mutation number estimates with respect to clinical stage
may be biased with the Finnish data because it includes
only specimens with tissue available for molecular analy-
sis. Advanced cancers may not be removed. Therefore, a
similar analysis was performed on a population-based
cancer registry [10] from the United States of America
(SEER 11 Regs Public-Use, Nov 2001 Sub (1992–1999)),
which records ages and stages at diagnosis regardless of
treatment (Table 2). The average age at diagnosis was 70.5
years, consistent with an estimate of six mutations to
colorectal cancer for the 108,275 white males and females
with stage data. Like the Finnish cancers, ages were similar
for SEER patients of different clinical stages, with an esti-
mate of six mutations for cancers with localized, regional
or distant clinical stages (Table 2 and Figure 1C).
Discussion
The exact identities and numbers of mutations required
for transformation are uncertain. With simple multistage
models [3-6,11], all cancers of a given type require the
same number of oncogenic mutations, but stochastic dif-
ferences in the times to accumulate these mutations allow
individual cancers to appear at different ages. Precisely
when and how quickly mutations accumulate are
unknown, but a basic premise is that cancer types requir-
ing more mutations will tend to appear later in life. There-
fore, numbers of mutations may be estimated from cancer
epidemiology. Colorectal cancer frequencies increase with
age, and the pattern of this increase is consistent with
approximately five to seven oncogenic mutations [3-6].
In this study numbers of mutations were estimated for
well-defined subgroups of colorectal cancers because bio-
logical heterogeneity may confound this type of quantita-
tive analysis. Such estimates should be considered rough
guides rather than absolute values because our model
does not account for all factors. Cancers were classified as
MSI+ or MSI-, and MSI+ cancers were further sub-classi-
fied as either hereditary (HNPCC) or sporadic. As
expected because one MMR mutation is inherited, esti-
mated numbers of critical mutations were less for MSI+
HNPCC cancers compared to sporadic MSI+ cancers.
However, sporadic MSI+ cancers required more than one
additional somatic mutation compared to HNPCC can-
cers. Of interest, a difference of more than a single muta-
tion has also been inferred between sporadic and FAP
cancers, with estimates of three to four mutations for FAP
cancers versus six for sporadic cancers [6,13], although
another analysis was consistent with a difference of only a
single mutation [14]. Therefore, germline mutations (APC
and MMR loci) in both common colorectal familial
Table 1: Finnish Colorectal Cancers Sample
Cancer Type Average 
Age (years)
Number (%) Most Likely Numbers of Mutations*
456789
HNPCC 50.3 29 (2.9) 0.08 0.43 0.39 0.09
Sporadic MSI+ 71.5 98 (12.4) 0.03 0.2 0.34 0.33 0.1
Sporadic MSI- 67.5 895 (87.6) 0.01 0.99
Sporadic MSI-
Stage A 68.6 187 (21.2) 0.09 0.75 0.16
Stage B 69.0 330 (37.3) 0.44 0.56
Stage C 65.2 246 (27.8) 0.8 0.2
Stage D 65.4 121 (13.7) 0.06 0.66 0.28
* Probabilities of the number of mutations required for cancer. Most likely values are underlined.BMC Cancer 2005, 5:126 http://www.biomedcentral.com/1471-2407/5/126
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cancer syndromes (FAP and HNPCC) appear to advance
progression by more than a single mutation relative to
their sporadic counterparts.
An epigenetic mechanism may help explain why sporadic
MSI+ cancers require more than one additional somatic
alteration relative to HNPCC cancers. Inactivation of the
normal MMR allele occurs through mutation (usually
LOH [15]) in HNPCC whereas MMR loss in sporadic
MSI+ cancers is associated with MLH1 promoter methyla-
tion [16,17]. CpG islands may be "protected" from meth-
ylation because most are unmethylated at birth and
usually remain unmethylated throughout life [18]. Epige-
netic MLH1 inactivation may require at least two cis acting
somatic alterations---loss of a mechanism that normally
prevents methylation, followed by the accumulation of
methylation at sufficient numbers of CpG sites to silence
expression.
In agreement with prior studies, there were seven muta-
tions estimated for sporadic MSI- Finnish cancers [4], and
seven or eight mutations for MSI+ cancers. A requirement
for more alterations before tranformation for sporadic
MSI+ compared to sporadic MSI- cancers may help
explain why sporadic MSI+ cancers are a minority of all
colorectal cancers and occur in slightly older patients
[19,20]. Although numbers of oncogenic mutations
before transformation are similar between sporadic MSI+
and MSI- cancers, their identities likely differ [7,8].
Colorectal cancers also differ by their extent of spread.
Progression to metastasis may involve a long sequence of
potentially rate limiting steps [21]. If invasion or metasta-
sis depends on mutations that arise after transformation,
advanced cancers should require more oncogenic muta-
tions and more time for progression (Figure 2). However,
ages at diagnosis and estimated mutation numbers did
not markedly differ between cancers of different clinical
stages.
Equivalent numbers of mutations regardless of clinical
stage are consistent with recent speculation that an inva-
sive potential is acquired early in progression [22], albeit
only rare cells actually form visible metastases. Primary
breast cancer expression patterns correlate with clinical
outcomes or metastases [22-25], suggesting that a propen-
sity to spread is already present at the time of transforma-
tion. Alternatively, all cancers may have the same abilities
to invade and metastasize, with clinical stage dependent
on random events that occur rapidly after transformation.
A short interval between transformation and detection
may help limit spread because clinical surveillance tends
to detect localized colorectal cancers [26-28].
Multistage models are mechanistically different from
tumor progression models and more consistent with a
hypothesis that mutations acquired early during progres-
sion help determine extent of invasion (Figure 3). Muta-
tions sequentially accumulate before transformation in
both models, but the adenoma-cancer sequence suggests
most cancer mutations start to accumulate after the age of
50 years in adenomas [7]. Such tumor progression
Cumulative colorectal cancer frequencies and patient ages at  diagnosis Figure 1
Cumulative colorectal cancer frequencies and 
patient ages at diagnosis. A) Finnish MSI-, and hereditary 
(HNPCC) and sporadic MSI+ colorectal cancers. B) Finnish 
MSI- cancers with respect to Duke's stage. C) SEER data with 
respect to clinical stage.
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imposes purpose to early mutations because each
additional mutation confers incremental changes to a
non-invasive adenoma phenotype. Therefore, tumor pro-
gression models would likely differ between MSI+ and
MSI- cancers because their biology and types of mutations
are quite different [7,8].
In contrast, mutations accumulate throughout life in
multistage models. Genetically engineered mice and
familial cancer syndromes reveal that many oncogenic
mutations are also compatible with normal phenotypes
[11], allowing for the possibility that many "cancer"
mutations may first accumulate in normal-appearing
colon very early in life. Such pretumor progression [11]
more readily allows for an invasive or metastatic cancer
phenotype at transformation because genetic progression
is uncoupled from tumor progression (Figure 2). Rather
than incremental stepwise changes in phenotype after
each new mutation, a tumor phenotype may only emerge
after several initially occult mutations accumulate in a
single normal appearing cell. In this way our multistage
model can apply to both MSI+ and MSI- cancers despite
their marked differences in types of mutations because
early critical mutations (whatever they are) do not visibly
change phenotype but instead accumulate in normal
appearing colon. Early or advanced sporadic MSI- colorec-
tal cancers appeared to require similar numbers of muta-
tions, consistent with the phenotype at cancer diagnosis
contingent on mutations acquired much earlier in life and
present at the time of transformation. However, ascertain-
ment bias may also be responsible for the similar fre-
quency-age distributions of colorectal cancers of different
clinical stages.
Progression to cancer has been modeled by a number of
investigators with different approaches and assumptions
[3-6,11-14,29,30]. In our previously reported approach
there is no growth until after the last required mutation
has been acquired [11]. In this paper we apply this model
to cancer subtypes instead of considering colorectal can-
cers as a single uniform disease. Modeling is potentially
more informative and specific when applied to distinct
cancer subtypes because their progression pathways can
differ. The ability to apply a simple multistage model to
different colorectal cancer subtypes that have marked
differences in final types of mutations and clinical out-
Table 2: SEER Colorectal Cancers
Cancer Type Average Age (years) Number (%) Number of Mutations*
All Cancers 70.5 108,275 6
Localized 70.9 44,773 (38.7) 6
Regional 70.5 42,380 (36.6) 6
Distant 69.5 21,122 (18.3) 6
* Most likely values
Mutation timing and numbers with respect to invasiveness Figure 2
Mutation timing and numbers with respect to inva-
siveness. If invasion or metastasis depends on mutations 
acquired after transformation, clinically higher stage cancers 
would be expected to require more time and mutations. 
However, if an invasive phenotype depends on mutations 
acquired before transformation, cancers of different clinical 
stages could require similar numbers of oncogenic mutations 
and times for progression.
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Multistage versus tumor progression models Figure 3
Multistage versus tumor progression models. In multi-
stage models, early mutations fail to confer visible changes in 
phenotype because they accumulate throughout life from 
birth. Tumors appear only after a cell has accumulated a crit-
ical number or combination of oncogenic mutations. In con-
trast, the adenoma-cancer sequence suggests most 
oncogenic mutations confer stepwise incremental changes in 
phenotype and accumulate much later in life in visible 
tumors.
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comes suggests its basic underlying premise (most critical
alterations first accumulate in normal colon) may be
correct.
Conclusion
The biology of cancer must underlie the epidemiology of
cancer. Here we illustrate that multistage models provide
conceptually plausible solutions even when colorectal
cancers are divided into biologically relevant and quite
different subtypes. Ages at cancer are consistent with five
or six somatic oncogenic mutations for hereditary
(HNPCC) MSI+ cancers and seven or eight mutations for
its sporadic counterpart. The apparent requirement for
more than one additional somatic mutation in sporadic
MSI+ cancers may reflect that MMR inactivation is com-
monly epigenetic, which may involve multiple steps. Ages
at MSI- cancers were consistent with six or seven onco-
genic mutations, with similar estimates for all clinical
stages, suggesting that mutations acquired very early in
life dictate the cancer phenotype at the time of transfor-
mation. Better integration of cancer epidemiology with its
biology remains a further challenge.
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